Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops, and manufactures injection and infusion systems for self-medication and offers related services. The company's products find application in the treatment of diabetes, infertility, growth disorders and various other clinical indications. Ypsomed's product portfolio includes autoinjectors, dual chamber pens, and pen injectors. The company also provides services ranging from design and development projects, flexible prototyping, human factors engineering, monitoring services, therapy management and IP landscape management to manufacturing and assembly infrastructure and registration support. Ypsomed offers solutions to physicians, and pharmaceutical and biotechnology companies. The company has operations in Switzerland, Europe, and North America, among others. Ypsomed is headquartered in Burgdorf, Switzerland.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Report Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Ypsomed Holding AG
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Ypsomed Holding AG Company Overview
- Ypsomed Holding AG Company Snapshot
- Ypsomed Holding AG Pipeline Products and Ongoing Clinical Trials Overview
- Ypsomed Holding AG - Pipeline Analysis Overview
- Business Description
- Ypsomed Holding AG - Key Facts
- Ypsomed Holding AG - Major Products and Services
- Ypsomed Holding AG Pipeline Products by Development Stage
- Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
- Ypsomed Holding AG Pipeline Products Overview
- mylife Loop
- mylife Loop Product Overview
- mylife Loop Clinical Trial
- mylife YpsoPump
- mylife YpsoPump Product Overview
- mylife YpsoPump Clinical Trial
- mylife YpsoPump 2.0 With Integrated CGM
- mylife YpsoPump 2.0 With Integrated CGM Product Overview
- UnoPen Zero
- UnoPen Zero Product Overview
- YpsoDose
- YpsoDose Product Overview
- YpsoDose Zero
- YpsoDose Zero Product Overview
- YpsoMate Zero 2.25 Pro
- YpsoMate Zero 2.25 Pro Product Overview
- YpsoMate Zero On
- YpsoMate Zero On Product Overview
- YpsoPod
- YpsoPod Product Overview
- Ypsomed Holding AG - Key Competitors
- Ypsomed Holding AG - Key Employees
- Ypsomed Holding AG - Key Employee Biographies
- Ypsomed Holding AG - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Ypsomed Holding AG, Recent Developments
- Sep 11, 2025: Ypsomed Receives FDA 510(K) Clearance For SmartPilot YpsoMate NS-A2.25
- Sep 02, 2025: Sharp Invests $20 Million in Autoinjector & Pen Assembly Lines to Meet Rising Demand for Injectables
- Sep 01, 2025: Ypsomed Receives FDA Clearance for SmartPilot
- Jul 01, 2025: Global First Dual GCG/GLP-1 Receptor Agonist for the Treatment of Obesity Launched in an Ypsomed Autoinjector in China
- Jun 27, 2025: Ypsomed opens production site in China
- Apr 07, 2025: Ypsomed and Sidekick Health Launch a Collaborative Digital Health Solution for Obesity Management
- Mar 18, 2025: Ypsomed and CamDiab launch mylife Loop on iOS
- Nov 13, 2024: Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care
- Oct 24, 2024: Ypsomed and BD to Enhance High-Viscosity Drug Delivery
- Oct 23, 2024: Ypsomed and BD collaborate to advance self-injection systems for high viscosity biologics
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Ypsomed Holding AG Pipeline Products and Ongoing Clinical Trials Overview
- Ypsomed Holding AG Pipeline Products by Equipment Type
- Ypsomed Holding AG Pipeline Products by Indication
- Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
- Ypsomed Holding AG, Key Facts
- Ypsomed Holding AG, Major Products and Services
- Ypsomed Holding AG Number of Pipeline Products by Development Stage
- Ypsomed Holding AG Pipeline Products Summary by Development Stage
- Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
- Ypsomed Holding AG Ongoing Clinical Trials Summary
- mylife Loop - Product Status
- mylife Loop - Product Description
- mylife Loop - Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop - Genesis
- mylife Loop - Randomised Open Label Clinical Trial Examining the Safety and Efficacy of the Android Artificial Pancreas System (AAPS) With Advanced Bolus-Free Features in Adults With Type 1 Diabetes: Extension Trial Using Ultra-Fast Acting Insulin
- mylife YpsoPump - Product Status
- mylife YpsoPump - Product Description
- mylife YpsoPump - An Open-label, Multi-centre, Randomised, Two Arm Single Period Parallel Study to Assess the Efficacy, Safety and Utility of Hybrid Closed-loop Glucose Control Compared to Standard Insulin Therapy Combined With Continuous Glucose Monitoring in Young People (=16 Years) and Adults With Cystic Fibrosis Related Diabetes (CL4P-CF Study)
- mylife YpsoPump - An Open-label, Multinational, Multicentre, Randomised, Single-period Parallel Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery Compared to Standard Insulin Therapy With CGM in Adults With Type 2 Diabetes
- mylife YpsoPump - Randomized Cross-over Study Comparing Insulin Pump Versus Full Closed-loop Automated Insulin Therapy in Type 2 Diabetic Patients Previously Treated With Insulin Pumps
- mylife YpsoPump - Targeting Beta-cell Function to Achieve Remission of Type 2 Diabetes (REACTIVATE). An Open-label, Single-centre, Randomised, Parallel Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery in Achieving Remission of Diabetes Compared to Standard Therapy With a Glucose Sensor in Adults With Recent Onset Type 2 Diabetes
- mylife YpsoPump 2.0 With Integrated CGM - Product Status
- mylife YpsoPump 2.0 With Integrated CGM - Product Description
- UnoPen Zero - Product Status
- UnoPen Zero - Product Description
- YpsoDose - Product Status
- YpsoDose - Product Description
- YpsoDose Zero - Product Status
- YpsoDose Zero - Product Description
- YpsoMate Zero 2.25 Pro - Product Status
- YpsoMate Zero 2.25 Pro - Product Description
- YpsoMate Zero On - Product Status
- YpsoMate Zero On - Product Description
- YpsoPod - Product Status
- YpsoPod - Product Description
- Ypsomed Holding AG, Key Employees
- Ypsomed Holding AG, Key Employee Biographies
- Ypsomed Holding AG, Subsidiaries
- Glossary
- Ypsomed Holding AG Pipeline Products by Equipment Type
- Ypsomed Holding AG Pipeline Products by Development Stage
- Ypsomed Holding AG Ongoing Clinical Trials by Trial Status
